=Ab s t r a c t = SmithMagenis syndrome (SMS) is a rare disorder with multiple congenital anomalies caused by a heterozygous interstitial deletion involving chromosome 17p11.2, where the retinoic acid-induced 1 (RAI1) gene is located, or by a mutation of RAI1. Approximately 90% of the patients with SMS have a detectable 17p11.2 microdeletion on fluorescence in-situ hybridization (FISH). SMS is characterized by mental retardation, distinctive behavioral features, craniofacial and skeletal anomalies, speech and developmental delay, and sleep disturbances. Although there are some intervention strategies that help individuals with SMS, there are no reported specific interventions for improving the outcome in children with SMS. Here, we report two cases of SmithMagenis syndrome. ( 
Ke y Wo r d s: Smith-Magenis syndrome, Chromosomal study, Fluorescence in-situ hybridization . The SMS is characterized by mental retardation, distinctive behavioral features, craniofacial and skeletal anomalies, speech and developmental delay, and sleep disturbance 1, 2) . Occasionally, systemic features such as cardiac and renal defects, cleft lip and/or palate have been observed. There are no specific treatment strategies available to improve the outcome of children with the SMS; the interventions are primarily supportive. Here we report two cases of SMS.
Ca s eRe p o r t Ca s e1
A 9-year-old girl with mental retardation presented to our hospital. The patient was born at 38 weeks gestation; the birth weight was 2,600 g. Development delay was diagnosed by 11 months of age; she could not sit, had a flat, broad nasal bridge, slanting palpebral fissures, protruding forehead, opened mouth, and slanted hands on physical examination.
The laboratory findings including the CBC, electrolytes, biochemistry, and thyroid function tests were normal. The patient was reported to have a normal conventional karyotype. The brain MRI showed no specific findings except for a mild ventriculomegaly, and the EEG was normal. At four years of age, the receptive language was at the 24 month level and the expressive language was at the 25 month level.
With time the features of the SMS became more apparent.
The patient had severe mental retardation, distinctive behavioral features, craniofacial and skeletal anomalies (including brachydactyly), speech and developmental delay, and sleep disturbance ( Fig. 1A-1D ). On the second cytogenetic study, an interstitial deletion of 17p11.2 was detected by conventional banding and deletion of the FL1 gene was confirmed by FISH using the Cytocell SMS probe (Fig 2A, 2B ). Because the patient sleeps for only four hours per day, melatonin was provided for the restoration of the circadian rhythm. In addition, early childhood intervention programs, special speech and language education, and multidisciplinary evaluations as well as care for the behavioral and systemic manifestations were provided.
Ca s e2
A 20-year-old man presented to our hospital for the evaluation of seizures. The patient was born at full term; the birth weight was 2,700 g. When he was six months old, he was found to have microcephaly on physical examination. The patient was diagnosed with mental retardation and had his first seizure at 11 years of age; his EEG showed focal . This disorder is rare in the general population. Prevalence estimates suggest an occurrence rate of 1:25,000 live births, with males and females affected equally 3) .
The diagnosis may not be immediately apparent, and in fact, it is not uncommon for a diagnosis of autism, PraderWilli syndrome, Down syndrome, velocardiofacial syndrome, Fragile X, or Angelman syndrome to be initially entertained 4) . The importance of a high index of clinical suspicion and skilled laboratory evaluation is needed to make this easily missed diagnosis 5) . Several physical anomalies are usually present including a broad head, prominent forehead, eye and vision abnormalities, flattened mid-face with a broad nasal bridge, underdeveloped cheekbones, down-turned mouth, a prominent jaw, short stature, small toes, inwardly bent fingers, and hypotonia 6) .
Approximately three quarters of the individuals with the SMS
show clinical signs of nerve damage in the extremities, including muscle weakness, walking difficulties, decreased deep tendon reflexes, and decreased sensitivity to temperature and pain 7) . In addition, developmental and behavioral concerns may be present such as, hyperactivity, impulsiveness, restlessness, distractibility, temper outbursts, and difficulty with sleep as well as progressive hearing loss 8, 13) . The treatment of affected individuals is supportive. There are no specific interventions available for children with the SMS.
In the first case, the patient showed the typical SMS clinical manifestations when she initially presented to the hospital. However, the karyotype was reported as normal by have smaller or larger deletions 13, 14) . A typical SMS patient is predicted to have about a -5 Mb deletion. However, patients harboring a deletion of <2 Mb and showing subtle or variant phenotypes may go undetected unless molecular studies are performed 1, 9) .
The patient was treated with melatonin for the sleep disturbance. The circadian rhythm associated with melatonin is closely associated with the sleep-wake cycle; administration of melatonin affects the latency to sleep onset, sleep consolidation, slow waves, sleep spindles, and REM sleep 10) .
The melatonin resulted in a dramatic improvement in sleep quality. Rosario et al 11) reported on the treatment of sleep disorders, in children with the SMS, with a selective β1-adrenergic antagonist plus melatonin.
In the second case, the clinical findings were not charac- 
